Technology | Stents Peripheral | February 17, 2016

Biotronik, Maquet Partner to Deliver Peripheral Vascular Devices in the U.S.

Partnership coincides with FDA approval for Biotronik’s Astron iliac self-expanding stent

Biotronik, Maquet, partnership, peripheral vascular devices, U.S. market, Astron self-expanding iliac stent

February 17, 2016 — Biotronik announced a partnership with Maquet Medical Systems USA to distribute Biotronik peripheral vascular devices in the United States.

The two companies will deliver a range of Biotronik products used to treat peripheral artery disease (PAD). These include the Passeo percutaneous transluminal angioplasty (PTA) balloon family; the Fortress reinforced sheath; the Cruiser-18 guide wire; and the Astron stent, which was recently granted U.S. Food and Drug Administration (FDA) approval for the treatment of iliac artery disease. This is Biotronik’s first FDA approval for a peripheral stent product.

Atherosclerotic disease of the iliac arteries, which supply blood to the pelvic organs and much of the lower limbs, can greatly impact a patient’s overall quality of life, limiting walking ability and leading to chronic pain and even morbidity. Endovascular interventions, including angioplasty and stenting, have become the first-line approach for the treatment of patients with simple and complex peripheral atherosclerotic lesions, including challenging-to-access iliac lesions. In 2014, an estimated 176,800 patients in the United States received an iliac stent, and that number is expected to grow annually.

“The Astron stent is a proven option for treating atherosclerotic disease of the common or external iliac arteries. Results of a 12-month study of Astron demonstrated a major adverse event (MAE) rate of just 2.1 percent, which is remarkably lower than the pre-specified performance goal of 15 percent,” said Mark W. Burket, M.D., of the University of Toledo Medical Center in Ohio, and national principal investigator of the BIOFLEX-I IDE study, which evaluated the performance of the Astron stent. “Astron’s 12-month target lesion revascularization rate was also low, at 1.4 percent. Based on these excellent results, I believe that U.S. physicians and patients will welcome this new technology.”

The Astron self-expanding nitinol stent system is designed to provide the specific performance characteristics required for iliac arteries. It features a peak-to-valley stent design with S-shaped articulating connecting bars to provide multi-directional flexibility while avoiding fish-scaling in tortuous arteries. The segmented architecture and strut thickness are engineered to provide optimal chronic outward force.

Astron stents are manufactured with Biotronik’s unique proBIO coating, a silicon carbide layer that reduces metal ion release from the stent surface into the surrounding tissue.

For more information: www.biotronik.com


Related Content

Feature | Stents Peripheral | Dave Fornell, Editor

November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) ...

Home November 06, 2019
Home
Technology | Stents Peripheral

October 5, 2018 — Veryan Medical Ltd has received Premarket Approval (PMA) for the BioMimics 3D Vascular Stent System ...

Home October 05, 2018
Home
News | Stents Peripheral

April 27, 2018 — Intact Vascular Inc. recently closed a Series C financing totaling $20 million. This financing is ...

Home April 27, 2018
Home
News | Stents Peripheral

July 26, 2017 — Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee ...

Home July 26, 2017
Home
News | Stents Peripheral

July 14, 2017 — Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational ...

Home July 14, 2017
Home
News | Stents Peripheral

April 28, 2017 — Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting ...

Home April 28, 2017
Home
News | Stents Peripheral

March 16, 2017 — W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular ...

Home March 16, 2017
Home
News | Stents Peripheral

March 2, 2017 — Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee ...

Home March 02, 2017
Home
News | Stents Peripheral

December 13, 2016 — Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal ...

Home December 13, 2016
Home
News | Stents Peripheral

December 8, 2016 — LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow ...

Home December 08, 2016
Home
Subscribe Now